Intravenous arketamine for treatment-resistant depression: open-label pilot study
Intravenous arketamine for treatment-resistant depression: open-label pilot study
复制标题
DOI：
10.1007/s00406-020-01110-5
复制
发表时间：
2020-02-20
影响因子：
4.7
通讯作者：
Quarantini, Lucas C.
中科院分区：
文献类型：
--
作者：
Leal, Gustavo C.;Bandeira, Igor D.;Quarantini, Lucas C.
我们的目的是分析氯胺酮的R(-)-对映体阿克他命治疗人类难治性抑郁症（TRD）的有效性和安全性。开放标签试点试验，7名TRD患者接受单次静脉输注阿氯胺酮（0.5 mg/kg）；主要观察指标为服药后24 h蒙哥马利-埃斯伯格抑郁评定量表（MADRS）的变化。平均MADRS从输注前的30.7降至1天后的10.4，平均差20.3点[CI 95% 13.6-27.0；P < 0.001]；游离几乎不存在。阿克他命可能对人类产生快速和持续的抗抑郁作用，并具有良好的安全性，就像之前对动物的报道一样；需要进一步的对照试验。
We aimed to analyze the efficacy and safety of arketamine, the R(-)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery-angstrom sberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean difference of 20.3 points [CI 95% 13.6-27.0; p < 0.001]; dissociation was nearly absent. Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed.